Clinical Trials · NCT05810597
A Research Study Looking at Similarity Between Tirzepatide Versions for Different Injection Devices
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Eli Lilly and Company
- Enrollment
- 65
- Start date
- Apr 2023
- Locations
- 3 sites, United States
- Primary endpoint
- Pharmacokinetics (PK): Maximum Concentration (Cmax) of Tirzepatide